Docosahexaenoic acid therapy in docosahexaenoic acid‐deficient patients with disorders of peroxisomal biogenesis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
A patient with classic Zellweger syndrome was treated with docosahexaenoic acid ethyl ester (DHA‐EE) for three months. Five other patients with Zellweger variants (four of them less than one‐year‐old and a five‐year‐old) were treated with DHA‐EE until normalization of the DHA levels in erythrocytes. When arachidonic acid (AA) concentration decreased, AA was added to the diet. Thereafter, a combined treatment with DHA plus AA followed, in a variable proportion that allowed the high levels of DHA in erythrocytes to be maintained. In the patient with Zellweger syndrome, DHA therapy produced an increase in plasmalogen and a decrease in 26:0 and 26:1. No clear clinical improvement could be detected in this patient during the short period of treatment with DHA‐EE. The most consistent clinical effect produced by DHA therapy in the other patients with disorders of peroxisomal biogenesis was visual improvement, even in those patients that were virtually blind before the treatment. In general, the developmental curve began to accelerate. The infants became more alert, acquired better visual and social contact and muscular tone improved, with the beginning of good head control. The liver tests tended to normalize and some patients showed a reduction of hepatomegaly. All these favorable changes occurred when the patients were taking the DHA‐EE alone. In some of the patients, muscular tone seemed to improve further after introducing AA supplements. From the biochemical point of view, the plasmalogen levels increased in most cases in erythrocytes, and the two ratios 26:0/22:0 and 26:1/22:0 decreased in plasma. In some patients, there was a tendency for 26:1 to increase in plasma and for 18:0 plasmalogen to decrease in erythrocytes when AA was introduced in the diet. The significance of these findings remains to be elucidated, but they stress the importance of strict monitoring and control of the polyunsaturated fatty acid status during DHA therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blood polyunsaturated fatty acids in patients with peroxisomal disorders. A multicenter study
Martinez, M., Mougan, I., Roig, M., & Ballabriga, A. (1994) · Lipids · doi:10.1007/bf02536332 · Cited by 54
Cited by
Perinatal biochemistry and physiology of long-chain polyunsaturated fatty acids
Innis, S. M. (2003) · The Journal of Pediatrics · doi:10.1067/s0022-3476(03)00396-2 · Cited by 505
Horrocks, L. A., & Farooqui, A. A. (2004) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2003.12.011 · Cited by 356
Dietary essential fatty acids and brain function: a developmental perspective on mechanisms
Wainwright, P. E. (2002) · Proceedings of the Nutrition Society · doi:10.1079/pns2001130 · Cited by 346
SanGiovanni, J. P., Parra-Cabrera, S., Colditz, G. A., Berkey, C. S., & Dwyer, J. T. (2000) · Pediatrics · doi:10.1542/peds.105.6.1292 · Cited by 256
Chevalier, A. C., & Rosenberger, T. A. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14032 · Cited by 50
Metadata
- Authors
- Martinez, M.
- Venue
- Lipids
- Publisher
- Wiley
- Published
- 1996-01
- Volume
- 31
- Issue
- 1Part2
- Pages
- S145-52
- ISSN
- 0024-4201 (ISSN-L)
- 1558-9307
- OpenAlex
- W1991550357
- Cited by
- 73
- References
- 1
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Docosahexaenoic acid therapy in docosahexaenoic acid‐deficient patients with disorders of peroxisomal biogenesis. https://app.cochat.ai/papers/10.1007/bf02637067
- The paper
- Martinez, M. (1996). Docosahexaenoic acid therapy in docosahexaenoic acid‐deficient patients with disorders of peroxisomal biogenesis. Lipids. https://doi.org/10.1007/bf02637067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.